Supplementary Figure S2 from High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study

Gao, Yan; Ping, Liqin; Shan, Changguo; Huang, He; Li, Zhiming; Zhou, Hui; Lai, Mingyao; Cai, Linbo; Bai, Bing; Huang, Cheng; Chen, Haoqing; Hong, Xiaoyu; Wang, Xiaoxiao; Huang, Huiqiang

doi:10.1158/2643-3230.28929715

Supplementary Figure S2 from High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study

journal contribution

posted on 2025-05-05, 07:20 authored by Yan Gao, Liqin Ping, Changguo Shan, He Huang, Zhiming Li, Hui Zhou, Mingyao Lai, Linbo Cai, Bing Bai, Cheng Huang, Haoqing Chen, Xiaoyu Hong, Xiaoxiao Wang, Huiqiang Huang

Supplementary Figure S2. Prevalence of detection and mutation load in tumor tissue, cerebrospinal fluid, and plasma.

Funding

National Natural Science Foundation of China (NSFC)

History

ARTICLE ABSTRACT

We report promising efficacy and good tolerability of Bruton tyrosine kinase (BTK) inhibitor ibrutinib in treatment of newly diagnosed PCNSL. Additionally, we explored the contribution of ctDNA profiling to predictive potential in this prospective study. The consistency of ctDNA clearance from CSF/plasma was associated with more sustained treatment response and survival.

Usage metrics

Keywords

Biomarkers Circulating tumor cells/DNA/exosomes Clinical Trial Results Phase II clinical trials Drug Targets Protein kinase & phosphatase drug targets Hematological Cancers Lymphomas

Licence

CC BY

Supplementary Figure S2 from High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study

Funding

National Natural Science Foundation of China (NSFC)

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports